Organic Active Ingredients TRIZ Cases

A pressurized wound rinse combines chlorhexidine and octenidine to cut microbial burden, shorten contact time, and limit deactivation issues.

New fused azadecalin compounds improve glucocorticoid receptor modulation by strengthening agonist blockade and therapeutic efficacy.

Stable free base and salt crystal forms improve RET inhibitor stability, solubility, and bioavailability while supporting lower-toxicity cancer treatment.

Defined hydrochloride crystal forms use XRPD and thermal profiling to improve solubility, stability, and polymorph control in ABL1 inhibitor development.

Human urine or blood exosomes are incubated with small non-coding RNA to maximize loading and improve targeted delivery to tumor cells.

Targeted MDM2 degradation via the ubiquitin-proteasome system improves stem cell osteogenic differentiation for bone regeneration.

Weekly or longer INS-3001 dosing maintains inhibition of calcium salt crystal exposure while limiting tissue accumulation and damage.

By linking KBU2046 to a bisphosphonate, these compounds improve bone delivery while inhibiting osteoclast-mediated degradation in cancer.

By inhibiting CKIP-1, dsRNA lowers inflammatory cytokines and promotes bone repair in rheumatoid arthritis where standard drugs fail to stop damage.

Defined oral dosing of NXC736 at 40-80 mg with once- or twice-daily cycles safely cuts absolute lymphocyte counts by 50% or more.

Salt and crystalline forms of a small-molecule GLP-1 agonist improve stability and manufacturability for oral diabetes treatment.

A solid dispersion tablet delivers a selective NaV1.8 inhibitor to relieve pain while reducing side effects and opioid abuse liability.

Small molecules targeting DHX33 RNA helicase address the lack of selective inhibitors for treating cancers such as lung, breast, and colon cancer.

A trifluoromethyl-modified BCL-2 inhibitor improves selectivity and efficacy in recurrent or refractory hematologic tumors, including treatment-intolerant cases.

A non-D2 antipsychotic uses TAAR1 and 5-HT1A activity to treat schizophrenia while reducing extrapyramidal and cardiovascular side effects.

PKLR-targeted JNK-IN-5A suppresses liver lipogenesis and HepG2 tumor growth, offering a small-molecule route for NAFLD and HCC.

A modified-release oral prodrug raises hydroxynorketamine plasma levels to improve depression treatment while reducing ketamine-related side effects.

Water-soluble fulvestrant prodrugs enable oral dosing through rapid hydrolytic release, improving bioavailability and reducing injection site reactions.

Porphyrin dimer photodynamic therapy primes tumor antigen release, then checkpoint inhibition boosts immune killing in recurrent esophageal cancer.

Novel heterocycle derivatives enhance dermal papilla cell proliferation to improve hair growth promotion and hair loss prevention.

Synthetic antibodies target specific LRP6 epitopes to block Wnt binding, disrupt signaling, and inhibit cancer cell growth.

Using dantrolene to inhibit SARS-CoV entry, replication, maturation, and release can lower viral load and improve fever and oxygen saturation.

HRG protein testing by ELISA or immunohistochemistry helps identify NSCLC patients likely to benefit from anti-HER3 treatment.

Combining RAD1901 with palbociclib inhibits resistant ER-positive breast tumors while limiting bone and uterine side effects.

Tetrahydrobenzo[1,4]thiazepine 1,1-dioxide RSV inhibitors improve antiviral activity and in vivo exposure for prevention and treatment.

Small molecules targeting the PCSK9 C-terminal domain enable oral LDL lowering while avoiding IV dosing limits and immune reaction risks.

Porous bead multiparticulates extend THC and CBD release up to 24 hours, stabilizing drug levels and enabling once-daily oral dosing.

Buffer and glycol or polyol cosolvents keep lisdexamfetamine oral solutions stable in water by limiting hydrolysis and oxidation.

Specific terpenoids from Antrodia camphorata and Anisomeles indica reduce fibrosis markers and protect kidney, liver, and vascular tissue.

Chemically modified sgRNA with Cas and an AAV donor improves stable homologous recombination in primary cells after transplantation.

Genetic profiling of IFIH1 and TRIM65 variants guides targeted psoriasis treatment to reduce inflammatory signaling and flare-ups.

A selective small-molecule CSF1R inhibitor depletes and repolarizes TAMs while avoiding off-target toxicity and excess CSF1 buildup.

Engineered particles or linkers co-localize mitotic kinase and checkpoint inhibitors to boost tumor killing while reducing systemic toxicity.

A borate-single polyol system keeps combined glaucoma eye drops stable, antimicrobial, and better tolerated with lower preservative levels.

A bilayer tablet releases antacid before the PPI to neutralize gastric acid, improving stability, dissolution, and onset without enteric coating.

Modular PRMT5 inhibitor scaffolds vary heteroaryl cores and substituents to improve anticancer efficacy while keeping synthesis manageable.

Staggered allogeneic CAR-T dosing improves cell expansion and persistence while balancing treatment efficacy and toxicity risk.

Small-molecule Smac mimetics antagonize IAP proteins to restore apoptosis sensitivity in resistant cancer cells.

Small-molecule CFTR modulators correct misfolded protein conformation and restore channel function to address cystic fibrosis at its source.

Bis-biguanide compounds such as alexidine are combined with chemotherapy to inhibit SCLC cell viability and invasion while addressing recurrence.

Radioprotectants and simplified Zr-89 antibody labeling improve purity, specific activity, and long-term storage stability.

Targets bacterial Mfd DNA repair to boost nitric oxide killing, curb resistance, and treat infections without eukaryotic toxicity.

A glycol-ether-free topical cannabinoid composition uses polyhydric alcohol and C10-C16 fatty excipients to boost skin delivery while staying stable.

A new daprodustat crystal form uses defined diffraction peaks to improve solubility, purity, and stability for pharmaceutical production.

A plant-derived formula (I) compound inhibits angiotensin-converting enzyme and enables foods and beverages that help lower blood pressure.

A patent-backed synthesis route for a CRF1 antagonist that lowers 17-hydroxyprogesterone and androstenedione, supporting lower glucocorticoid doses in CAH.

Targeted AGT dsRNA uses RISC-mediated gene silencing to lower blood pressure while reducing multi-drug adherence and side-effect burdens.

Specific dissolution targets and granule particle sizes create IVIVC for tadalafil and dutasteride, reducing repeat clinical trials.

Modified pyridinobenzodiazepines improve DNA sequence-selective binding and cytotoxicity while addressing edema and fatigue seen with earlier PBD agents.

Specific crystalline, amorphous, and salt forms improve powder flow, compaction, and stability while preserving drug dissolution and bioavailability.

Amorphous dasatinib dispersed in polymers maintains oral efficacy despite gastric acid reducers and reduces pharmacokinetic variability.

Acid salt crystal forms of piperidylindole compounds improve stability and handling while preserving factor B modulation for complement-related diseases.

Thiophene derivatives inhibit xanthine oxidase to lower uric acid while aiming to reduce hypersensitivity, cutaneous, and cardiovascular risks.

Bioavailable DHA and EPA forms enable cardiovascular and cognitive improvements within hours, avoiding the delay of chronic supplementation.

PLA2 and metalloprotease inhibitors stabilize suspected sepsis before diagnosis, improving antibiotic use and reducing ARDS risk.

Chemically modified omega-3 VLC-PUFAs drive inflammation resolution, restore cellular homeostasis, and protect neurons with fewer side effects.

A dual small-molecule inhibitor blocks TLR7 and TLR9 signaling to reduce TNF-α, NF-κB, and MAPK driven inflammation in autoimmune disease.

Sirolimus inhibits type IV collagen synthesis and secretion in vascular endothelial cells to treat matrix-driven vascular disorders.

Ion pairing nicotine with lipophilic organic acids improves oral mucosal absorption while limiting pH-driven flavor instability and evaporation.

Defined crystalline salt forms control phase unpredictability and improve stability, formulation consistency, and bioavailability for KRasG12C therapy.

An anionic surfactant and basic substance prevent impermeable film formation in high-dose tablets, improving dissolution and oral absorbability.

Substituted 3-methyl pyrazines address the lack of effective SHP2 small molecules by enabling allosteric inhibition for disease treatment.

Stable GLP-1R agonist salt crystal forms resist grinding, compression, and humidity-driven changes, improving pharmaceutical processability.

Dual HCK and BTK inhibition with Compound (I) addresses MYD88-driven disease resistance and supports apoptosis in resistant lymphoma cells.

Targeting IRE1α and SASP activity with metformin-based compositions helps limit senescence and support vascular repair in ocular disease.

Bispecific compounds link ERK5 binding to E3 ligase recruitment, enabling low-dose proteasomal degradation for cancer and inflammatory disease treatment.

Covalently binding chitosan in a polyurethane hydrogel delivers antibacterial wound dressing performance without releasing chitosan into the wound.

PFI-63 and PFI-90 improve histone demethylase inhibition to disrupt oncogenic transcription and trigger apoptosis in cancer cells.

Fermented ginseng promotes reelin and VEGF-C to improve lymphatic vessel function, helping reduce swelling, lymphedema, and skin wrinkles.

Formula I compounds boost ex vivo CD34+ stem and progenitor cell expansion, increasing transplantable cell dose and supporting safer engraftment.

Salt selection and crystal form screening improve solubility, bioavailability, and pharmacokinetic behavior for an FGFR-targeting compound.

Small-molecule ferroportin inhibitors reduce iron transport and absorption to treat iron overload with better stability and longer action.

Gelatin-coated cochlear implant electrodes cut insertion trauma while delivering dexamethasone with short- and long-term anti-inflammatory release.

A solid-forming topical anesthetic balances freeze-thaw stability, fast drying, skin adherence, and easy peel-off removal.

A single AAV donor template with multiple homology-arm cassettes enables multiplex genome editing while reducing nuclease and template complexity.

A norepinephrine reuptake inhibitor paired with a non-myorelaxing hypnotic helps keep the pharyngeal airway open during sleep.

Long-term oral magnesium with potassium, hydration, and EKG monitoring helps convert atrial fibrillation to sinus rhythm and reduce recurrence.

A β-AR agonist paired with a peripherally acting β-blocker improves cognition while limiting cardiac and other peripheral side effects.

A plant-based enteral and oral formula uses pea protein, balanced fats, and prebiotic fiber to improve digestibility while avoiding common allergens.

Imidazopiperazine compounds block CBP and P300 bromodomain interactions to improve inhibition where existing therapies lack effective targets.

Loaded mesenchymal stem cell extracellular vesicles improve treatment consistency across inflammatory, degenerative, cancer, infectious, and aging conditions.

Specific Formula I-III compounds inhibit 15-PGDH to modulate prostaglandin levels and improve treatment options for related disorders.

Modified end groups and PEGylation stabilize nucleic acid polyplexes, reducing aggregation and toxicity for lung delivery.

Gentle PEG-based microvesicle isolation preserves vesicle integrity for collagen VII delivery, reducing blistering and scarring in epidermolysis bullosa.

Modified ACE-tRNAs reassign premature stop codons, improve EF1α-assisted suppression, and restore full-length protein translation.

Imidazopyrimidine small molecules modulate IL-17A to replace costly injectable biologics with more accessible and convenient dosing.

Electrostatic cationic nanocarriers drive contrast agents deep into cartilage and hold them there longer, improving imaging at lower doses.

Targeted RNAi oligonucleotides suppress HBsAg mRNA across HBV genotypes, enabling durable antigen knockdown and reduced viral protein expression.

Rapamycin analogs are tuned for mTORC1 selectivity to preserve lifespan benefits while reducing mTORC2-linked metabolic side effects.

New diazabicyclic inhibitors block class A, B, C, and D β-lactamases to restore β-lactam antibiotic activity against resistant bacteria.

Specific excipient combinations keep levcromakalim soluble and stable in aqueous eye drops, enabling glaucoma treatment without prodrugs or high DMSO.

Systemic leoligin delivery via inhalation or buccal routes helps protect hypoxic tissue without invasive emergency procedures.

Perfluoroalkyl ether groups added to nucleic acids improve cell membrane permeability while preserving target activity and reducing reliance on toxic carriers.

Acetate or citrate buffered one-part clinical media avoids bicarbonate precipitation while preserving cell viability during storage and transport.

Novel small-molecule CD73 inhibitors block adenosine pathway immunosuppression, restoring anti-tumor immunity and supporting immunotherapy efficacy.

Combining gedatolisib with hormone therapy blocks PI3K/mTOR and AR signaling to overcome resistance in prostate cancer.

By pairing Pioglitazone with MEK inhibitors, this case shows how adipogenesis can overcome EMT plasticity, TGFβ resistance, and metastasis.

Submicron spironolactone particles in water overcome skin barrier limits to reach the pilosebaceous unit at 1-3 mm dermal depth.

Cell-permeable PARG inhibitor compounds improve selectivity in cancer cells with DNA replication stress and sensitize them to DNA-damaging agents.

Chelator-grafted polymers or nanoparticles in dialysis fluid selectively remove metal cations while limiting cytotoxicity and off-target loss.